Anti-inflammatory mechanism of resveratrol’s Triglyceride-lowering effect in hyperlipidemia: a meta-analysis integrated network pharmacology and molecular dynamics simulation
Clinical and Experimental Medicine · 24.07.2025 · 25 (1)
DOI: 10.1007/s10238-025-01809-6 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Clinical and Experimental Medicine, online erschienen am 24.07.2025. Verfasst von Yinyan Shao und 1 weiteren Autor:innen. Beteiligte Einrichtung: Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medicine University, Tiyuchang Road 453, Hang…. Hauptthemen laut MEDLINE: Hyperlipidemias, Triglycerides, Resveratrol, Anti-Inflammatory Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
To elucidate resveratrol's (RES) effects on blood lipids and underlying mechanisms, this study integrated meta-analysis with network pharmacology and molecular dynamics simulations. Randomized controlled trials (RCTs) were systematically retrieved, screened, and assessed for quality, followed by meta-analysis. Separately, shared targets of RES and hyperlipidemia were identified, and protein-protein interaction networks were constructed using Cytoscape. Core targets were validated via molecular docking and 100 ns molecular dynamics simulations. Meta-analysis of seven RCTs (n = 337) revealed that RES significantly reduced triglycerides (TG) but showed no significant effects on total cholesterol, low-density lipoprotein, or high-density lipoprotein. Network pharmacology identified 794 RES-hyperlipidemia overlapping targets, with PPI analysis prioritizing three pro-inflammatory hubs: Interleukin-6 (IL6), Interleukin-1β (IL1B), and tumor necrosis factor. Molecular dynamics simulations confirmed stable RES binding to these targets, with strong binding free energies of - 13.95, - 11.86, and - 11.28 kcal/mol, respectively. RES specifically lowered TG but not other lipids, potentially through direct modulation of inflammatory pathways rather than classic lipid metabolism regulators. Comprehensive analysis indicated RES as a promising therapeutic candidate for hypertriglyceridemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medicine University, Tiyuchang Road 453, Hangzhou, 310007, Zhejiang, China. yinyanshao2024@163.com.
- Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medicine University, Tiyuchang Road 453, Hangzhou, 310007, Zhejiang, China.
Zitieren
APA
Shao, Y., & Shi, J. (2025). Anti-inflammatory mechanism of resveratrol’s Triglyceride-lowering effect in hyperlipidemia: a meta-analysis integrated network pharmacology and molecular dynamics simulation. Clinical and Experimental Medicine, 25(1). https://doi.org/10.1007/s10238-025-01809-6
Vancouver
Shao Y, Shi J. Anti-inflammatory mechanism of resveratrol’s Triglyceride-lowering effect in hyperlipidemia: a meta-analysis integrated network pharmacology and molecular dynamics simulation. Clinical and Experimental Medicine. 2025;25(1). doi:10.1007/s10238-025-01809-6
BibTeX
@article{Shao2025,
author = {Shao, Yinyan and Shi, Junwei},
title = {Anti-inflammatory mechanism of resveratrol’s Triglyceride-lowering effect in hyperlipidemia: a meta-analysis integrated network pharmacology and molecular dynamics simulation},
journal = {Clinical and Experimental Medicine},
year = {2025},
volume = {25},
number = {1},
doi = {10.1007/s10238-025-01809-6}
}
EUVIMED